The Importance of Albumin Infusion Rate for Plasma Volume Expansion Following Major Abdominal Surgery

NCT ID: NCT02728921

Last Updated: 2017-04-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-04-30

Study Completion Date

2016-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To study if plasma volume expansion is influenced by the rate at which a colloidal solution is administered in patients with a systemic inflammatory response induced by major abdominal surgery.

Randomization will be performed postoperatively at the day of surgery with a 1:1 ratio with no stratification and the study drug will be given as a slow (3 hours) or rapid (30 minutes) intravenous infusion.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Major surgery is one of many triggers of a systemic inflammatory response syndrome (SIRS), which disrupts the normal regulation of transcapillary fluid exchange with tissue oedema and hypovolemia as a consequence. Hypovolemia will amplify the inflammatory reaction by reducing cardiac output and oxygen delivery, which creates a vicious circle. Fluid therapy is therefore a cornerstone in the perioperative treatment patients subjected to major surgery. However, even if fluid therapy is life saving it is also associated with side effects such as further oedema formation, coagulopathy and further endothelial dysfunction.

From a clinical perspective, it is therefore important that the fluid administered to antagonize hypovolemia as far as possible remains intravascularly. Colloids are macromolecules for which the vessel wall has a low permeability and proponents of colloid containing fluids argues that less volume is required for equal plasma volume compared to crystalloids. However, extravasation of colloids is not only a function of the vessel wall permeability but is also dependent on the volume of fluid to that is filtered across the vascular wall, which in turn depends on the trans-capillary hydrostatic pressure. This means that administration of colloids in a way that minimizes the increase in capillary pressure could be important for the plasma volume expanding effect.

In support of this hypothesis is the experimental result that the plasma volume expansion of a colloidal solution can be affected by the rate of administration (Bark et al., 2013). If this finding proves to be valid also in a clinical setting, it will be very important for how colloidal solutions are prescribed in the clinic and may change current clinical practice in which suspected hypovolemia often is treated with a bolus infusion of fluid. This study intend to investigate whether these findings can be reproduced after a so-called Whipple's operation or after major gynaecological cancer surgery.

Study patients will be studied after these procedures because because they are large and standardized operations that trigger an inflammatory condition with capillary leakage and therefore can be considered as a model for major surgical procedures as well as ICU patients with SIRS triggered by for example sepsis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pancreatic Neoplasms Urogenital Neoplasm Systemic Inflammatory Response Syndrome Hypovolemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

5% Albumin infusion 30 min

Intravenous infusion of 5% Albumin at a dose of 10ml/kg during 30 min.

Group Type ACTIVE_COMPARATOR

5% Albumin infusion 30 min

Intervention Type DRUG

Intravenous infusion of 5% Albumin at a dose of 10 ml/kg during 30 minutes. Dose is based on ideal weight.

5% Albumin infusion 3 hours

Intravenous infusion of 5% Albumin at a dose of 10ml/kg during 3 hours. Dose is based on ideal body weight

Group Type EXPERIMENTAL

5% Albumin infusion 3 hours

Intervention Type DRUG

Intravenous infusion of 5% Albumin at a dose of 10 ml/kg during 3 hours. Dose is based on ideal weight.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

5% Albumin infusion 30 min

Intravenous infusion of 5% Albumin at a dose of 10 ml/kg during 30 minutes. Dose is based on ideal weight.

Intervention Type DRUG

5% Albumin infusion 3 hours

Intravenous infusion of 5% Albumin at a dose of 10 ml/kg during 3 hours. Dose is based on ideal weight.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. The patient is scheduled for non-emergent Whipple operation or major gynaecological cancer surgery.
2. Indication for fluid therapy as judged by the anaesthesiologist in charge and at least one at least one of the following criteria is fulfilled:

* Positive "leg raising test" (pulse pressure increase \> 9% or stroke volume increase by more than 10% as measured with cardiac ultrasound.
* Central venous oxygen saturation (ScvO2) \< 70%.
* Plasma lactate \> 2.0 mmol/l.
* Urine output \< 0.5 ml / kg for the latest hour.
* Respiratory variation of the inferior vena cava of more than 15% as measured by ultrasound.
* Systolic pressure \< 100 mmHg, mean arterial pressure \< 55 mmHg
3. Age 40 and above
4. Written consent by patient to participate in the study

Exclusion Criteria

1. Hypersensitivity to the active drug/ the tracer.
2. Signs of postoperative bleeding.
3. History of heart failure.
4. The responsible physician considers that there are strong reasons to administrate another fluid or same fluid but in another way or in a different volume than those included in the protocol.
5. Pregnancy
6. Clinical judgment by the investigator or the treating physician that the patient should not participate in of the study for reasons other than described above.
Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Region Skane

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Peter Bentzer, MD

Role: PRINCIPAL_INVESTIGATOR

Region Skåne

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Skåne University Hospital, Region Skåne

Lund, , Sweden

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Sweden

References

Explore related publications, articles, or registry entries linked to this study.

Statkevicius S, Bonnevier J, Bark BP, Larsson E, Oberg CM, Kannisto P, Tingstedt B, Bentzer P. The importance of albumin infusion rate for plasma volume expansion following major abdominal surgery - AIR: study protocol for a randomised controlled trial. Trials. 2016 Dec 7;17(1):578. doi: 10.1186/s13063-016-1714-5.

Reference Type DERIVED
PMID: 27923389 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2013-004446-42

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Albumin in Cardiac Surgery
NCT02560519 COMPLETED PHASE4